Search DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 1 - 10 of 319

Investigator:Brian Gordon

Title:Tau phosphorylations in biofluids in relation to disease progression of autosomal dominant AD

Date of Request:12/17/2024

Status:pending approval

ID:DIAN-D2436

Aim 1:To map combinations of tau phosphorylations in biofluids in dominantly inherited AD.

Aim 2:To associate a composite tau score to disease progression.

Investigator:n/a

Title:Biogen-DIAN-TU BIIB080 Design

Date of Request:11/20/2024

Status:approved

ID:DIAN-D2435

Aim 1:Patient characteristics of preclinical AD with EYO -10 to +10, including (but not limited to): % amyloid positive, baseline characteristics (especially baseline tau PET), rate of change in tau PET and CDR-SB;

Aim 2:How is tau PET composite derived; If we were to include plasma p-tau enrichment, what would be the threshold?

Aim 3:Sample size calculation and assumptions for 2 year and 1 year tau PET assessment If we were to combine both DIAN and sporadic AD for this preclinical study, what would be the assumptions and sample size?

Investigator:Gengsheng Chen

Title:Identify proteins associated with integrated biological and clinical staging using the ADRC and DIAN cohorts

Date of Request:11/01/2024

Status:pending approval

ID:DIAN-D2434

Aim 1:Identify proteins associated with integrated biological and clinical staging using DIAN cohort.

Aim 2:Test if the identified proteins in Aim1 are associated with the cortical thickness and hippocampal volume.

Aim 3:Examine function pathways for the proteins identified in Aim1.

Investigator:Raquel Sánchez-Valle

Title:Cortical asymmetry as a tool to monitor individuals with Autosomal Dominant Alzheimer’s Disease progression

Date of Request:10/10/2024

Status:approved

ID:DIAN-D2433

Aim 1:To evaluate brain asymmetry using the Cortical Asymmetry Index in a cohort of both symptomatic and asymptomatic Autosomal dominantly inherited Alzheimer’s disease mutation carriers

Aim 2:To estimate longitudinal cortical asymmetry changes in ADAD and to evaluate cortical asymmetry as a tool to study Alzheimer’s disease progression

Investigator:Jasmeer Chhatwal (contact) / Lei Liu and Michael Wolfe (MPIs)

Title:Leveraging proteomics to identify γ-secretase-dependent pathways and changes in BBB function that drive ADAD

Date of Request:09/25/2024

Status:pending approval

ID:DIAN-D2432

Aim 1:Establish plasma and CSF proteomic signatures related to variant-specific gamma-secretase function/Aβ proteoform production.

Aim 2:Characterize changes in correlation between CSF and plasma proteins in order to develop and validate proteomics-derived markers of BBB integrity in ADAD.

Investigator:Yi Su

Title:Tracer harmonization for amyloid and tau PET imaging using statistical and deep learning techniques

Date of Request:09/25/2024

Status:approved

ID:DIAN-D2431

Aim 1:Harmonize amyloid PET tracers

Aim 2:Harmonize tau PET tracers

Aim 3:Estimate the effect of multiple tracers in clinical trials

Investigator:None

Title:APOE4 homozygous and autosomal dominant inheritance (PSENs/APP mutation) clinical characteristics and biomarker differences of Alzheimer's disease patients

Date of Request:09/08/2024

Status:pending approval

ID:DIAN-D2430

Aim 1:To explore whether there are differences in clinical characteristics and biomarkers between APOE4 homozygous and autosomal dominant (PSENs/APP mutation) patients with Alzheimer's disease who do not carry APOE4 genotype, further identify the interaction between APOE4 and Aβ changes, and guide the individualized diagnosis and treatment of clinical Alzheimer's disease patients.

Investigator:n/a

Title:Evaluation of biomarkers changes associated with dominantly inherited Alzheimer’s disease to identify neurodegenerative and inflammatory biomarkers appropriate for Alzheimer’s clinical trials

Date of Request:09/05/2024

Status:approved

ID:DIAN-D2429

Aim 1:We hypothesize that findings from this cohort are likely to be informative for characterizing and monitoring sporadic forms of Alzheimer’s Disease as well.

Aim 2:We will focus on (1) the establishment of specific composite score to integrate several biomarkers to predict clinical outcomes sensitive to early disease and (2) the relationship of these biomarkers to markers of pathways of interest for future drug development (eg. anti-inflammatory pathways).

Investigator:Jonathan Kipnis

Title:How the skull and blood contribute immune cells to Alzheimer's disease (AD) pathology

Date of Request:09/03/2024

Status:approved

ID:DIAN-D2428

Aim 1:Analyze snRNAseq data from DIAN samples from the dataset published in Brase, et al. Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. Nat Commun 14, 2314 (2023). https://doi.org/10.1038/s41467-023-37437-5 to compare against a mouse derived gene signature of brain engrafting immune cells.

Investigator:Mustapha Bouhrara

Title:Establishing Noninvasive Biomarkers of Axonal Degeneration in Autosomal Dominant Alzheimer's Disease using Multishell Diffusion MRI

Date of Request:08/27/2024

Status:approved

ID:DIAN-D2427

Aim 1:The purpose of this study is to investigate axonal degeneration in Autosomal Dominant Alzheimer's Disease (ADAD) using advanced multishell diffusion magnetic resonance imaging (MRI) analyses, including Constrained Neurite Orientation Dispersion and Density Imaging (C-NODDI), to better understand the timing, location, and mechanisms of axonal degeneration in ADAD, and to identify potential biomarkers for AD progression and therapeutic efficacy.

Aim 2:To investigate axonal degeneration in ADAD using multishell diffusion MRI analyses, including C-NODDI, NODDI, and SMI.

Aim 3:To map axonal degeneration alterations as a function of years from symptom onset and integrate them within the temporal biomarker model of ADAD.

Aim 4To examine the relationship between axonal degeneration alterations and CSF- or blood/plasma-based biomarkers of AD pathology in ADAD.